Kura Oncology’s Komzifti is approved for treating advanced cases of acute myeloid leukemia with an NPM1 mutation. A Syndax Pharmaceuticals drug is already approved in this indication, but Kura says its drug has advantages in safety and patient convenience.
The post FDA Approves Kura Oncology Leukemia Drug, Teeing Up Competition With Syndax Pharma appeared first on MedCity News.
